Nov 22 (Reuters) - Halozyme Therapeutics Inc HALO.O:
HALOZYME WITHDRAWS PROPOSAL TO ACQUIRE EVOTEC FOLLOWING EVOTEC'S UNWILLINGNESS TO ENGAGE IN DISCUSSIONS
REITERATE RAISED 2024 GUIDANCE FOR REVENUE OF $970-$1,020 MILLION AND ADJUSTED EBITDA OF $595-$625 MILLION
TO DATE, EVOTEC HAS BEEN UNWILLING TO ENGAGE WITH US TO EXPLORE A POTENTIAL COMBINATION AND A COMPANY SPOKESPERSON HAS PUBLICLY COMMENTED THAT ITS GOAL IS TO REMAIN AN INDEPENDENT COMPANY
Source text: ID:nPn4cwbXMa
Further company coverage: EVTG.DE
(Gdansk Newsroom)
(((( gdansk.newsroom@thomsonreuters.com ; +48 587785269; ));))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。